Dan Zhang
Research Subjects
Dan Zhang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Le Tang
Postgraduate Training Base of Shenyang Women’s and Children’s Hospital of Jinzhou Medical University, Shenyang, Liaoning, China
2 shared publicationsQing Sun
Postgraduate Training Base of Shenyang Women’s and Children’s Hospital of Jinzhou Medical University, Shenyang, Liaoning, China
2 shared publicationsHaijiao Wang
Shenyang Women’s and Children’s Hospital, Shenyang, China
1 shared publication- Hengyu Cai
Department of Anesthesiology, Shenyang Women’s and Children’s Hospital, 110011 Shenyang, Liaoning, China
1 shared publication Leilei Wang
C Department of Obstetrics and Gynaecology , Shengjing Hospital of China Medical University , Shenyang , China
1 shared publicationLihong Yu
A Department of Obstetrics and Gynaecology , Shenyang Women's and Children's Hospital , Shenyang , China
1 shared publication
Latest Publications
- Open Access
- 8 July 2025
- Published by IMR Press in Clinical and Experimental Obstetrics & Gynecology
- Vol. 52 (7)
Influencing Factors and Predictive Value of Postpartum Hemorrhage Following Cesarean Myomectomy: A Retrospective Cohort Study
Background: Postpartum hemorrhage (PPH) is a major cause of maternal mortality, and uterine fibroids are a common condition that may contribute to this risk. This study aimed to determine the risk factors for PPH following cesarean myomectomy and to evaluate their predictive value. Methods: We conducted a retrospective analysis of 1002 women with fibroids ≥4 cm in diameter who underwent cesarean myomectomy at the Shenyang Women’s and Children’s Hospital from January 2014 to November 2022. The PPH and non-PPH groups consisted of 109 and 893 patients, respectively. Patient, clinical, and surgical data were collected from medical records. Factors associated with PPH were identified through univariate and multivariable logistic regression analyses. A receiver operating characteristic (ROC) curve analysis was used to assess the predictive value of independent risk factors for PPH. Propensity score matching analysis was used to determine whether bilateral uterine artery ligation before myomectomy and the use of potent uterotonic drugs during this procedure protected against PPH. Results: Independent risk factors for PPH included multiple fibroids, specific sites of fibroids (located in the lower segment of the uterus, cervix, uterine cornu, or adjacent to the uterine vessels or the interstitial part of the fallopian tube), a longer surgery duration, and a larger fibroid size (diameter >7.5 cm for single fibroids and total diameter >14.5 cm for multiple fibroids). The results of the propensity score matching analysis indicated that bilateral uterine artery ligation and the administration of potent uterotonic drugs before myomectomy were protective factors against PPH. ROC curve analysis showed that both the maximum diameter of a single uterine fibroid and the sum of the maximum diameters of multiple uterine fibroids are predictive of PPH risk. Conclusions: Cesarean myomectomy is relatively safe for fibroids located at non-specific sites with a diameter ≤7.5 cm (single) or a total diameter ≤14.5 cm (multiple). The duration of surgery should be minimized. In high-risk cases, bilateral uterine artery ligation and the administration of potent uterotonic drugs before myomectomy should be considered.
- 8 July 2025
- Published by IMR Press in Clinical and Experimental Obstetrics & Gynecology
- Vol. 52 (7)
Open AccessInfluencing Factors and Predictive Value of Postpartum Hemorrhage Following Cesarean Myomectomy: A Retrospective Cohort Study
Background: Postpartum hemorrhage (PPH) is a major cause of maternal mortality, and uterine fibroids are a common condition that may contribute to this risk. This study aimed to determine the risk factors for PPH following cesarean myomectomy and to evaluate their predictive value. Methods: We conducted a retrospective analysis of 1002 women with fibroids ≥4 cm in diameter who underwent cesarean myomectomy at the Shenyang Women’s and Children’s Hospital from January 2014 to November 2022. The PPH and non-PPH groups consisted of 109 and 893 patients, respectively. Patient, clinical, and surgical data were collected from medical records. Factors associated with PPH were identified through univariate and multivariable logistic regression analyses. A receiver operating characteristic (ROC) curve analysis was used to assess the predictive value of independent risk factors for PPH. Propensity score matching analysis was used to determine whether bilateral uterine artery ligation before myomectomy and the use of potent uterotonic drugs during this procedure protected against PPH. Results: Independent risk factors for PPH included multiple fibroids, specific sites of fibroids (located in the lower segment of the uterus, cervix, uterine cornu, or adjacent to the uterine vessels or the interstitial part of the fallopian tube), a longer surgery duration, and a larger fibroid size (diameter >7.5 cm for single fibroids and total diameter >14.5 cm for multiple fibroids). The results of the propensity score matching analysis indicated that bilateral uterine artery ligation and the administration of potent uterotonic drugs before myomectomy were protective factors against PPH. ROC curve analysis showed that both the maximum diameter of a single uterine fibroid and the sum of the maximum diameters of multiple uterine fibroids are predictive of PPH risk. Conclusions: Cesarean myomectomy is relatively safe for fibroids located at non-specific sites with a diameter ≤7.5 cm (single) or a total diameter ≤14.5 cm (multiple). The duration of surgery should be minimized. In high-risk cases, bilateral uterine artery ligation and the administration of potent uterotonic drugs before myomectomy should be considered.
- Open Access
- 11 February 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 310 (1) , 103-111
Human umbilical cord mesenchymal stem cells improve uterine incision healing after cesarean delivery in rats by modulating the TGF-β/Smad signaling pathway
Objective: Although human umbilical cord-derived mesenchymal stem cells (HU-MSCs) have attracted increasing attention because of their pivotal functions in the process of wound healing, the underlying molecular mechanisms have been poorly understood. It has been shown that the TGF-β/Smad signaling pathway plays an important role in the process of scar formation. The present study focused on exploring whether HU-MSCs improve uterine incision healing after cesarean delivery in rats via the TGF-β/Smad signaling pathway. Study Design: Pregnant rats were randomly assigned to three groups, including the NP group, incision-injected group (HU-MSCs1 group), and tail vein-injected group (HU-MSCs2 group), and 30 days after cesarean section, sampling was carried out to further explore the specific mechanisms from tissue and protein levels. Results: HU-MSCs secretion could inhibit the fibrosis of scar tissue. We observed that the TGF-β induced expression of TGF-β1, Smad2, and Smad3 was attenuated upon HU-MSCs treatment in scar tissue, while the decrease in TGF-β3 expression was enhanced by HU-MSCs. Furthermore, HU-MSCs treatment accelerated wound healing and attenuated collagen deposition in a damaged uterine rat model, leading to the promoting of uterine incision scarring. In addition, the expression of alpha-smooth muscle actin (a-SMA) was enhanced by HU-MSCs treatment. Conclusion: HU-MSCs transplantation promotes rat cesarean section uterine incision scar healing by modulating the TGF-β/Smad signaling pathway.
- 11 February 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 310 (1) , 103-111
Open AccessHuman umbilical cord mesenchymal stem cells improve uterine incision healing after cesarean delivery in rats by modulating the TGF-β/Smad signaling pathway
Objective: Although human umbilical cord-derived mesenchymal stem cells (HU-MSCs) have attracted increasing attention because of their pivotal functions in the process of wound healing, the underlying molecular mechanisms have been poorly understood. It has been shown that the TGF-β/Smad signaling pathway plays an important role in the process of scar formation. The present study focused on exploring whether HU-MSCs improve uterine incision healing after cesarean delivery in rats via the TGF-β/Smad signaling pathway. Study Design: Pregnant rats were randomly assigned to three groups, including the NP group, incision-injected group (HU-MSCs1 group), and tail vein-injected group (HU-MSCs2 group), and 30 days after cesarean section, sampling was carried out to further explore the specific mechanisms from tissue and protein levels. Results: HU-MSCs secretion could inhibit the fibrosis of scar tissue. We observed that the TGF-β induced expression of TGF-β1, Smad2, and Smad3 was attenuated upon HU-MSCs treatment in scar tissue, while the decrease in TGF-β3 expression was enhanced by HU-MSCs. Furthermore, HU-MSCs treatment accelerated wound healing and attenuated collagen deposition in a damaged uterine rat model, leading to the promoting of uterine incision scarring. In addition, the expression of alpha-smooth muscle actin (a-SMA) was enhanced by HU-MSCs treatment. Conclusion: HU-MSCs transplantation promotes rat cesarean section uterine incision scar healing by modulating the TGF-β/Smad signaling pathway.
- Open Access
- 8 November 2023
- Published by Springer Nature in European Journal of Medical Research
- Vol. 28 (1) , 1-8
Molecular mechanisms of uterine incision healing and scar formation
Wound healing is a tandem process involving inflammation, proliferation, and remodeling, through which damage is repaired and ultimately scar tissue is formed. This process mainly relies on the complex and extensive interaction of growth factors and cytokines, which coordinate the synthesis of various cell types. The loss of normal regulation in any part of this process can lead to excessive scarring or unhealed wounds. Recent studies have shown that it is possible to improve wound healing and even achieve scar-free wound healing through proper regulation of cytokines and molecules in this process. In recent years, many studies have focused on accelerating wound healing and reducing scar size by regulating the molecular mechanisms related to wound healing and scar formation. We summarized the role of these factors in wound healing and scar formation, to provide a new idea for clinical scar-free healing treatment of uterine incisions.
- 8 November 2023
- Published by Springer Nature in European Journal of Medical Research
- Vol. 28 (1) , 1-8
Open AccessMolecular mechanisms of uterine incision healing and scar formation
Wound healing is a tandem process involving inflammation, proliferation, and remodeling, through which damage is repaired and ultimately scar tissue is formed. This process mainly relies on the complex and extensive interaction of growth factors and cytokines, which coordinate the synthesis of various cell types. The loss of normal regulation in any part of this process can lead to excessive scarring or unhealed wounds. Recent studies have shown that it is possible to improve wound healing and even achieve scar-free wound healing through proper regulation of cytokines and molecules in this process. In recent years, many studies have focused on accelerating wound healing and reducing scar size by regulating the molecular mechanisms related to wound healing and scar formation. We summarized the role of these factors in wound healing and scar formation, to provide a new idea for clinical scar-free healing treatment of uterine incisions.
- 13 June 2017
- Published by Taylor & Francis in Hypertension in Pregnancy
- Vol. 36 (3) , 247-258
Therapeutic benefit of mesenchymal stem cells in pregnant rats with angiotensin receptor agonistic autoantibody-induced hypertension: Implications for immunomodulation and cytoprotection
Immunomodulation by mesenchymal stem cells (MSCs) is potentially important for maintaining peripheral tolerance. Preeclampsia may be due to maternal immune rejection of the genetically foreign fetus. This study aimed to investigate the biological function of human umbilical cord–derived mesenchymal stem cells (HU-MSCs) for the treatment of angiotensin receptor agonistic autoantibody (AT1-AA)-induced hypertension during pregnancy. HU-MSCs were isolated, cultured, and labeled in vitro. AT1-AA and HU-MSCs were administered to pregnant rats. Green fluorescent protein (GFP)–positive HU-MSCs infused in vivo were identified by immunofluorescence. Systolic blood pressure (SBP) was evaluated. The effects of HU-MSCs on fetal weight, kidney burden, and spiral artery remodeling, as well as on the expression of tumor necrosis factor α (TNF-α), interleukin 10 (IL-10), and heme oxygenase 1 (HO-1), were investigated. The SBP levels in the HU-MSC-treated pregnant hypertension rats decreased by gestational day 19. The reduction in fetal weight was largely ameliorated after HU-MSC treatment. Lesion burden in the kidney was attenuated and spiral artery remodeling was improved in HU-MSC-treated pregnant hypertension rats. However, green fluorescent protein (GFP)–labeled cells were sparingly observed in the kidney and placenta. Intravenous infusion of HU-MSCs into AT1-AA-induced rats significantly downregulated serum TNF-α levels and upregulated IL-10 levels, concomitant with increased placenta and mesometrial triangle (MT) HO-1 expression. Taken together, intravenous infusion of HU-MSCs ameliorates AT1-AA-induced pregnancy hypertension, intrauterine growth retardation, kidney impairment, and spiral artery remodeling impairment. Moreover, the potential benefits of HU-MSCs may be attributable to both an interference with the pathogenic immune response and a paracrine cytoprotective action.
- 13 June 2017
- Published by Taylor & Francis in Hypertension in Pregnancy
- Vol. 36 (3) , 247-258
Therapeutic benefit of mesenchymal stem cells in pregnant rats with angiotensin receptor agonistic autoantibody-induced hypertension: Implications for immunomodulation and cytoprotection
Immunomodulation by mesenchymal stem cells (MSCs) is potentially important for maintaining peripheral tolerance. Preeclampsia may be due to maternal immune rejection of the genetically foreign fetus. This study aimed to investigate the biological function of human umbilical cord–derived mesenchymal stem cells (HU-MSCs) for the treatment of angiotensin receptor agonistic autoantibody (AT1-AA)-induced hypertension during pregnancy. HU-MSCs were isolated, cultured, and labeled in vitro. AT1-AA and HU-MSCs were administered to pregnant rats. Green fluorescent protein (GFP)–positive HU-MSCs infused in vivo were identified by immunofluorescence. Systolic blood pressure (SBP) was evaluated. The effects of HU-MSCs on fetal weight, kidney burden, and spiral artery remodeling, as well as on the expression of tumor necrosis factor α (TNF-α), interleukin 10 (IL-10), and heme oxygenase 1 (HO-1), were investigated. The SBP levels in the HU-MSC-treated pregnant hypertension rats decreased by gestational day 19. The reduction in fetal weight was largely ameliorated after HU-MSC treatment. Lesion burden in the kidney was attenuated and spiral artery remodeling was improved in HU-MSC-treated pregnant hypertension rats. However, green fluorescent protein (GFP)–labeled cells were sparingly observed in the kidney and placenta. Intravenous infusion of HU-MSCs into AT1-AA-induced rats significantly downregulated serum TNF-α levels and upregulated IL-10 levels, concomitant with increased placenta and mesometrial triangle (MT) HO-1 expression. Taken together, intravenous infusion of HU-MSCs ameliorates AT1-AA-induced pregnancy hypertension, intrauterine growth retardation, kidney impairment, and spiral artery remodeling impairment. Moreover, the potential benefits of HU-MSCs may be attributable to both an interference with the pathogenic immune response and a paracrine cytoprotective action.